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Friends of Grover Powers. The late Daniel Darrow, a long-time and dis.
tinguished member of your faculty, in 1946, on dedicating his first 76 sci.
entific papers in a bound volume to Grover Powers, inscribed it as follows:
"To Grover F. Powers, whose faith in people made this work possible."
Faith in people is perhaps the best way to characterize Grover Powers'
basic attitude in life and this faith colored all his work in pediatrics and
medical education. In lauding Grover Powers, as a truly lasting and vital
influence on so many, we can take joy in the model department he built
here at Yale. He brought Milton Senn to Yale, and there came and con-
tinue to come since then, under Dr. Cook's leadership, a group of idealistic,
dedicated, and able young men and women among whom are clearly to-
morrow's great names.
Grover Powers is a man of quality; quality in its classic Greek sense:
how to live with grace, and intelligence, and bravery and mercy. It might
be well to say a few things about what Grover Powers is not. In a recent
book, Theodore White, talking about our current society called it the
"Digital Society." Digits for the boys who are drafted, digits for the social
security and income tax people, digits on credit cards and union cards,
digits replacing familiar telephone exchanges, the electronic recordings that
answer the telephone at airports and railway stations as well. Grover
Powers' total life thrust has been the other way: to individualize and
cherish each for what he is and what is best in him, has been his great con-
cern through the years. Grover Powers, by choice, is a teacher and clini-
cian; he trusts in people, and he possesses an enormous sense of mercy and
compassion for the sick and a great deal of unashamed love for children
who are pretty perfect and adults who are not so perfect. He never showed
fretful anxiety about sick children but rather intelligent concern, which he
was able to communicate promptly, often by telephone, to his associates.
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He would call at the end of his daily ward rounds, Dr. Taffel or Dr. Ger-
man, or Dr. Wilson, or Dr. Canfield, the entire brain trust sometimes, re-
peating "that six hats are better than one, especially if they are top hats."
We never felt he was by-passing the residents when he did this, because
all of us were so busy trying to solve the puzzle at hand with him that we
didn't feel left out. Nor did his clinical problem solving limit itself to
clinical consultations. I remember a little baby who was mentally retarded
and had a high-pitched cry and a high fever which he thought could not be
infectious. He called John Brobeck from pathology to come down and talk
to us about hypothalamic fevers.
It is now commonplace to talk about the New Pediatrics. People who
don't know Dr. Powers may not know that he was indeed a great innovator
in pediatrics. Many practices which are now absolutely routine were started
by him. He was "thoroughly modern."
Dr. Marian C. Putnam, I believe, was the first fulltime member of any
pediatric department who was an analytic psychiatrist, and later Dr. Edith
Jackson joined the department as a fulltime psychiatrist. Some of you may
remember Miss Rice, a social worker who did weekly ward rounds at a
time when that was considered radical. You may remember a classic paper
by Powers entitled "Humanizing Hospital Experiences."' This modest
paper contains in it all the things we now take so for granted in hospital
practice: Liberalizing visiting hours, having stockings on children's feet
when they are cold, giving parents easy access to the child, feeding the sick
child what he likes, not what he should have, and trying to cause the least
amount of pain, and many more. Rooming-in as a medical-school sponsored
activity was encouraged by Dr. Powers and home visits with new babies
became routine for all of us on the house staff and in the medical school.
He felt that above all one should do no harm. He had a horror of iatrogenic
disease. I might say a word about this because it will lead directly to the
subject of my talk on routine smallpox vaccination which is, after all, a
deliberate and universal iatrogenic disease. Once when we saw a child who
was suffering from a serious complication of smallpox vaccination, I, who
had just worked for three years in a smallpox area during my Army serv-
ice pointed out fairly blithely that occasional serious complications were
bound to occur with anything, and that this is simply a risk we have to
take. I remember that is exactly what I said: "That is a risk we have to
take." He looked very sad. He looked at me, he looked at the baby, finally
he said: "Who has to take? Who asked him?" It was a comment that
hasn't been forgotten.
It is my view that, in the United States, the relative risk of a newborn
child contracting smallpox from an accidental importation is considerably
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smaller than the known risk of routine primary smallpox vaccination for
all infants, as currently advocated.
Routine smallpox vaccination was highly justified when virulent small-
pox was a real threat to the lives of young children in this country. There
is no question that almost universal smallpox vaccination is responsible for
the eradication of the disease from North America. The freedom from the
virulent, major form of smallpox that this country has enjoyed since 1949
is widely but erroneously believed to be evidence of a high level of im-
munity among our population. Actually, the United States is no better
protected than Sweden, Poland, Great Britain, or the rest of Western
Europe, where in 1963, the importation of four cases resulted in 141
secondary cases with eleven deaths.' As a nation, we can be said to be well
vaccinated but not well immunized. While it is true that fatalities from
smallpox are less common in anyone who has ever been vaccinated, it is
also true that within one year after primary vaccination the chance of an
attack of smallpox is reduced to 1/1,000 of that in the unvaccinated, within
three years to 1/200, within ten years to 1/8, within twenty years to 1/2,
and after twenty years there is little protection from clinical infection. It
is clear from the above that routine primary vaccination of all infants does
not, even in our current situation, intend to protect against the disease,
which might be encountered in a trip to an endemic area twenty years
hence.! The principle reason for early vaccination is the feeling, on many
people's part, that the risk of serious complications-particularly en-
cephalitis-is significantly less in the young and is largely limited to pri-
mary rather than repeat vaccination.'
Credit for first employing an attenuated vaccine for smallpox goes to the
late Dr. Thomas Rivers whose strain of vaccinia had been passed in chick
embryo tissue cultures.' Dr. Rivers was pleased to note that this attenuated
strain, free of bacteria and given intradermally, caused no skin necrosis or
scars and a minimal amount of fever or systemic reactions. Unfortunately,
he found that revaccination with the standard strain of vaccinia 12 months
later resulted in a major vaccinoid reaction in the majority of these chil-
dren.' He discarded this attempt because he feared that primary vaccination
with the attenuated strain did not provide as much immunity against small-
pox as the standard strain.' It is clear to us now, however, that primary
vaccination in this country need not be highly effective for immediate pro-
tection against smallpox, because in the absence of exposure to smallpox it
is not the primary nor, indeed, the second or third vaccination which is
likely to be of significance in protection against smallpox if one considers
that it is virtually impossible for an American child to be exposed to small-
pox until he travels into a smallpox endemic region in Africa or Asia,
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probably after his 18th birthday. On the other hand, it is the primary vac-
cination which is of greatest concern from the point of serious complications.
Most of the deaths of vaccination are encountered in primary vaccinations,
as are most cases of postvaccinal encephalitis.8 Clearly, the initial sensitizing
experience with vaccinia antigen need not result in as high a degree of
immunity against smallpox as was formerly believed, provided only that
it indeed caused lesser complications than the routine vaccine universally
in use.
The strain used in these studies is derived from the "First Revived
Strain" of Dr. Thomas Rivers which originated from the dermal vaccine
virus of the New York Board of Health. A specimen from Lot 611 of this
original strain, received by Dr. Rivers at the Rockefeller Institute of Medi-
cal Research in 1931, was subsequently propagated by him through four
intratesticular passages in rabbits, and then serially in a medium of chick
embryonic tissue in Tyrode's solution. Virus from the 34th passage in this
series was then passed six times through rabbit testes and cultivated serially
in chick embryonic tissue by Dr. R. F. Parker, of Western Reserve Uni-
versity.' Material in the 59th passage in this series was received by us in
1946 at the Walter Reed Army Institute of Research and further passed
on chicken-egg chorioallantoic membranes for an additional nineteen pass-
ages. This strain is designated as CVI-78; its infectivity titer is 8.4 TCID
50/ml., and it is free of bacteria or known extraneous agents.
In 1948, we began to work with this strain of vaccinia virus. It was
clear from the start that this further attenuated strain (CVI-78) caused
less skin necrosis in rabbits and children regardless of the route of ad-
ministration.
The attenuated strain of vaccinia virus was at first used in those children
who are now excluded from routine vaccination in infancy and who are at
risk from accidental contamination with vaccinia from a vaccinated sibling
or classmate. There are some 90,000 children each year with infantile
eczema among the 5,000,000 infants born and they are potentially at risk
from eczema vaccinatum. Many studies have shown that eczema vaccinatum
is a much more serious disease in accidentally contaminated infants than
an elective primary vaccination of eczema patients who only occasionally
will generalize their virus infection. We, therefore, limited our first ex-
perience with the attenuated strain to the elective vaccination of children
with eczema.
Table 1 shows the dosage schedule used in the first 594 children who
received CVI-78. It should be noted that 406 of the children received
routine multiple pressure vaccination while the remainder received sub-
cutaneous inoculation of varying dosages of vaccine diluted 1:100 or
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TABLE 1. DOSAGE SCHEDULE, ROUTE OF ADMINISTRATION, AND TYPE OF
VACCINATION OF 594 PATIENTS RECEIVING ATTENUATED VACCINIA VIRUS
Vaccination wvith attenuated vaccinia zirus of patients eith eczema
Dosage schedule and
route of administration Number of patients receiving
Primary Total
vaccination Revaccination vaccinations
1. Multiple pressure 366 40 406
2. Subcutaneous
0.3 ml. 1:100 71 28 99
3. Subcutaneous
0.3 ml. 1 :1000 24 5 29
4. Subcutaneous
0.1 ml. 1:1000 58 2 60
Total patients 519 75 594
1:1000. Table 2 shows the delivered virus dose for these different methods
of inoculation which ranged from the variable inoculum of multiple pres-
sure vaccination to a dose of 1,000 TCID50 for the 0.1 ml. of 1:1000 sub-
cutaneous inoculation.
Table 2 also shows the geometric mean of neutralizing titers one month
after such vaccination for each dosage schedule. It should be noted that
routine vaccination of normal children receiving standard vaccine results
in a geometric mean titer of 48.5. Sero conversion occurred in all children
receiving even the lowest inoculated dose of 1,000 TCID50, although the
TABLE 2. RELATIONSHIP OF GEOMETRIC MEAN OF NEUTRALIZING TITERS
EXPRESSED IN TERMS OF TISSUE CULTURE INFECTION DOSES 50 (TCIDro)
ONE MONTH AFTER PRIMARY VACCINATION WITH DIFFERENT DOSAGE SCHEDULES
Serologic studies followuing primary vaccination weith CVI-78
Dosage schedule and Geometric mean Number of
route of administration TCID 50 neutralizing titer patients
Multiple pressure Variable 52.06 101
Subcutaneous
0.3 ml. 1:100 30,000 54.36 54
Subcutaneous
0.3 ml. 1:1000 3,000 34.36 22
Subcutaneous
0.1 ml. 1 :1000 1,000 25.35 38
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geometric mean of the neutralizing titer was somewhat lower in this group
than in those receiving a higher inoculum.
Figure 1 compares a distribution of maximal fevers after primary vac-
cination of 36 normal children receiving a standard vaccine (Dryvax) with
fevers in children suffering from eczema receiving either multiple pressure
or subcutaneous inoculation of CVI-78 vaccinia. Normal children receiving
standard vaccine showed a higher percentage of elevated temperature re-
PRIMARY VACCINATIONS FEVER CHART
M.P. = MULTIPLE PRESSURE
S.C. = SUBCUTANEOUS
9W8100.90FEM
101° 102.90F 2
103°11050 F
36 175 70 24 58
M.P. M.P. S.C. S.C. S.C.
DRYVAX 0.3ml 0.3m1 0.1mI
1:100 1:1000 1:1000
FIG. 1. Distribution of maximal temperature elevations of normal children receiv-
ing standard vaccine compared to five dosage schedules of attenuated vaccinia in
eczema patients.
sponses than eczematous children ieceiving the attenuated strain. Table 3
compares the geometric mean of the neutralizing titer with the various
routes and doses of inoculation to the maximal fever shown. It will be
seen that there is no evidence that higher fevers result in higher antibody
titers.
Table 4 classifies local reactions in an arbitrary fashion from 0 to 4+
in the eczematous children receiving primary vaccination with the attenu-
ated strain. It is of interest that subcutaneous inoculation does not result
in a skin lesion of any kind. Thus, a 1 to 3 + reaction refers to the degree
of erythema and subcutaneous local tenderness and swelling at the site of
vaccination generally 10 days after inoculation. Multiple pressure vac-
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TABLE 3. RELATIONSHIP OF GEOMETRIC MEAN OF NEUTRALIZING ANTIBODIES
ONE MONTH AFTER PRIMARY VACCINATION WITH THE MAXIMAL FEBRILE
RESPONSES PRODUCED BY PRIMARY VACCINATION TO ATTENUATED VACCINIA VIRUS
Relationship of neutralizing titer (geometric mean) to maximum febrile reaction
98°-100.9° F. 101-102° F. 103°-1050 F.
Dosage schedule
and route of Geometric No. of Geometric No. of Geometric No. of
administration mean patients mean patients mean patients
Multiple pressure 53.88 87 42.12 11 30.00 1
Subcutaneous
0.3 ml. 1:100 58.29 40 51.44 10 33.47 3
Subcutaneous
0.3 ml. 1:1000 31.83 17 44.60 5 0 0
Subcutaneous
0.1 ml. 1:1000 25.42 33 25.20 3 24.49 2
cinations, on the other hand, are similar in appearance to those obtained
with standard vaccine except for a reduction in erythema and swelling and
only an occasional occurrence of axillary lymphadenopathy. The single 4+
reaction was a case of mild erythema multiforme, in an incidence similar to
that expected with routine primary vaccination.
TABLE 4. LOCAL REACTIONS OF PATIENTS WITH ECZEMA FOLLOWING PRIMARY
VACCINATION WITH ATTENUATED VACCINIA VIRUS ADMINISTERED BY
DIFFERENT DOSAGE SCHEDULES AND ROUTES OF ADMINISTRATION
Local reactions follotwng primary vaccinations twith CVI-78
Dosage schedule
and route of Local reactions Number of
administration 0 +or++ +++ +++-J+ vaccinations
Multiple pressure no take
equivocal take
13% 84% 2% 1% 174
Subcutaneous
0.3 ml. 1:100 61% 37% 2% 0% 67
Subcutaneous
0.3 ml. 1:1000 59% 41% 0% 0% 24
Subcutaneous
0.1 ml. 1:1000 69% 31% 0% 0% 58
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Table 5 attempts to roughly classify systemic reactions. Any degree
malaise was classified as 1 +, a single case of erythema multiforme was
classified as 3 +. It will be seen that close to 90%o of children had no
systemic reaction to this vaccine. It should be stressed that generalization
of virus did not occur.
It is not known what the incidence of eczema vaccinatum is in the
deliberate primary vaccination of children with eczema because it is a
procedure specifically contraindicated in pediatric practice. On the other
hand, each year, the American Red Cross consultants on the vaccinia-
immune gammaglobulin distribution program, receive approximately 60
TABLE 5. SYSTEMIC REACTIONS FOLLOWING PRIMARY VACCINATION
Severity of systemic reactions after primary vaccinations teith CVI-78
Dosage schedule
and route of Severity of reaction
administration 0 + +++ Total
Multiple pressure 84% 15% 1% 175
Subcutaneous
0.3 ml. 1:100 89% 11% 0%0 71
Subcutaneous
0.3 ml. 1 :1000 88% 12% 0% 24
Subcutaneous
0.1 ml. 1 :1000 88% 12% 0% 58
calls for vaccinia-immune gammaglobulin in situations where children
with eczema had been intentionally vaccinated, while an additional 60 calls
relate to children accidentally contaminated with vaccinia, usually, from
a sibling.8 If the incidence of eczema vaccinatum in deliberate vaccination
of children with eczema is as low as 1 and 100, then 60 cases of eczema
vaccinatum requiring vaccinia-immune gammaglobulin therapy represents
6,000 erroneous deliberate vaccinations per year of children with eczema.
This figure is just possible considering the great number of eczematous
children in the United States. If one case of eczema vaccinatum would
occur from 100 deliberate vaccinations, then there should have been at least
5 cases of eczema vaccinatum among our 519 primary eczema vaccinations,
but there were happily none. If the incidence of the disease is 1 in 50 there
should have been 10. It would seem, in any case, that it is worthwhile to
proceed in widening this experience, limiting oneself, for the time being,
to children at risk from eczema vaccinatum.
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If present experience continues, it is likely that those who wish to con-
tinue routine primary vaccination will be able to use an attenuated strain
for primary vaccination and follow this subsequently with the current
vaccine when protection against smallpox becomes desirable. I believe such
a vaccine will be available to physicians within a few years.
It would seem logical, inasmuch as the next two or three years are un-
likely to make any difference whatever in terms of exposure to smallpox,
that routine primary vaccination with the current virulent strain could be
halted and that subsequently, if desired, the two-step immunization with
attenuated live vaccinia could be instituted. Conversely, the primary vac-
cination with the modified attenuated strain of vaccinia could be done at
such time as an indication exists and routine vaccination discontinued.
If routine primary vaccination were innocuous, and if it provided "herd
immunity" by giving partial protection, and if it interfered with the spread
of smallpox upon an importation, a case could be made for continuing with
the current method and the current strain. On the other hand, we are not
accomplishing what we are trying to do because, while young children are
excellently protected against smallpox, they are not in circulation sufficiently
to be an important population barrier to importation-on the other hand,
young adults have a relatively high rate of susceptibility. For example,
85%o of our military recruits respond to routine smallpox revaccination
with a major reaction as defined by the W.H.O. Expert Committee.'0
To truly provide an immune population, revaccination of the entire
population every three to five years would be essential. While this is highly
desirable for nurses, physicians, and other hospital personnel, as well as
the Armed Forces, and yearly revaccination is advised for individuals en-
gaged in foreign travel to smallpox-endemic regions, nobody has seriously
suggested mass campaigns in the population at large.
The mortality and morbidity from routine infant smallpox vaccination
in this country is now truly appalling when compared to the risk of small-
pox.' Completely accurate information on the incidence of vaccination
complications is not available, since it is not reportable unless fatal. How-
ever, even fatal complications often are not identified as such.8 In 1963
there were 398 requests to the American Red Cross for vaccinia-immune
gammaglobulin for the treatment of complications. Analysis of data ob-
tained from a review of questionnaires received from 19,616 physicians
surveyed by us suggested that the estimated number of complications in
1963 was approximately 3,000, with ten to eighteen deaths among a total
of fourteen million persons vaccinated. Many of these complications would
be prevented if physicians excluded from vaccination those individuals who
suffer from conditions which make the procedure unsafe.8
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We believe that the death rate from routine vaccination is between 1 and
1.5 per million vaccinees, with a much higher death rate in primary than
in repeat vaccination. The morbidity data for 1963 suggest that the total
cost of hospitalization was in excess of $80,000 per year for treatment of
patients with complications. The incidence of post-vaccinia encephaltis
would appear to be at least 1/100,000 in primary vaccinees, and this would
assume 60 cases in 1963. The last smallpox death in the United States
following an importation occurred in 1948, but since that time there have
probably been 200 to 300 deaths from smallpox vaccination. Assuming a
mortality rate of 30% from variola major, the number of smallpox cases
in the United States would have had to be between 600 and 900 during
this period to equal the mortality from vaccination.!
No other routine immunization procedure in this country has anything
like the morbidity and mortality of routine smallpox vaccination. Ad-
mittedly, it is difficult to assess what constitutes a complication. By defini-
tion, a successful vaccination represents a deliberate iatrogenic infection,
the expected morbidity of which includes fever as well as other systemic
symptoms, and local inflammation and necrosis is an expected finding. No
one has yet defined clearly what findings beyond the expected constitute
major morbidity. But, by comparison, it is conservatively estimated that
before the advent of measles immunization approximately 500 children
died each year as a result of measles, and measles encephalitis occurs as
often as 1 in 400 cases. If, in order to prevent these 500 deaths and the
numerous other serious complications of wild measles, the Enders attenu-
ated measles vaccine had promised solid protection and life-long immunity
against measles, but also had caused a mortality of 1 to 1.5 per million
vaccinees and had resulted in an incidence of encephalitis of 1 in 100,000,
I do not believe this product would have been licensed in this country. In
all prophylactic, diagnostic, and therapeutic efforts, the risk of the pro-
cedure is always considered in relation to the risk of the condition we try
to prevent, diagnose, or cure. The majority of workers in the field of public
health sincerely feel that the current morbidity and mortality from routine
vaccination is "the price we have to pay" for keeping our country free of
smallpox. Those responsible for the care of children, on the other hand,
must now look to the welfare of each child and remember the dictum "First,
do no harm." At the very least, parents should have a choice to decide
this matter in collaboration with their physician and based on the current
risk information.
In view of the availability of N-methylisatin-,8-thiosemicarbazone18 and
vaccinia-immune gamma globulin for prophylaxis after exposure to small-
pox,' and the availability in the near future of less virulent vaccinia strains,
10
Volume 41, August, 1968Attenuated smallpox vaccine KEMPE
current recommendations regarding routine vaccination need to be re-
evaluated.
Let me stress that smallpox vaccination has been and continues to be the
single most effective immunizing procedure in the eradication of smallpox
in endemic reservoirs. But in view of the current small risk of the disease
in this country, it has now become possible for us to assess the risk of the
procedure against the risk of the disease and to suggest that routine pri-
mary vaccinations with the current virulent strain has an undue morbidity
and mortality; it should be replaced as speedily as possible by less danger-
ous methods of providing a minimum basic antigenic experience by the use
of vaccinia virus in a modified, less virulent strain. Until such strains are
commercially available, routine vaccination might well be suspended and
vaccinations with the current vaccine limited to groups actually at risk of
exposure.
In this progress report I have tried to tell you what came of Dr. Powers'
question to me 20 years ago: What price does the child pay for routine
smallpox vaccination? We hope that an attenuated strain may lessen the
price.
Let us recall with Osler that the great possession of any University is
its great names. It is not the "pride, pomp, and circumstance" of an institu-
tion which bring honor; not its wealth, nor the number of its schools, not
the students who throng its halls, but the men who have trodden in its
service the thorny road through toil, even through hate, to the serene
abode of fame, climbing "like stars to their appointed height." One such
great name in Yale history is Grover Powers. We best honor him by
loyally supporting the next generation of young teachers of pediatrics in
the eternal continuum of a University.
I am grateful to you for inviting me to deliver this lecture honoring
Grover Powers, and I hope that I have done him honor.
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